Compare BLMN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | AQST |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.2M | 504.0M |
| IPO Year | 2012 | 2007 |
| Metric | BLMN | AQST |
|---|---|---|
| Price | $6.10 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $8.38 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | ★ 106.71 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $4,213,346,000.00 | $67,430,000.00 |
| Revenue This Year | $2.07 | $10.08 |
| Revenue Next Year | $1.81 | $49.60 |
| P/E Ratio | $63.60 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $5.19 | $2.22 |
| 52 Week High | $10.70 | $7.55 |
| Indicator | BLMN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 45.90 |
| Support Level | $5.40 | $3.70 |
| Resistance Level | $6.12 | $4.32 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 48.28 | 22.09 |
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.